Press release
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the results.\n\n\nWebcast and Conference Call and Details\n\n\nInvestors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.\n\n\nFor analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIf9cd65655e5444119df91cd4891157f8. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.\n\n\nSelected Recent Events\n\n\n\nReported interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, an investigational RNAi therapeutic for treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs. Key results from Part 1 of the study in normal healthy volunteers included the following:\n\n\nMean maximum reduction in soluble RAGE (sRAGE) as measured in serum after two doses of 92 mg on Day 1 and Day 29 was 80% with a maximum reduction of 90%\n\n\nDuration of pharmacologic effect persisted for at least 6 weeks\n\n\n\n\n\n\nMean reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose of 92 mg was 75% with a maximum reduction of 92%\n\n\n\nMean maximum reduction of 56% with a maximum reduction of 68% in serum sRAGE was also observed after a single dose of 92 mg\n\n\n\nSafety and tolerability\n\n\nOverall, no patterns of adverse changes in any clinical safety parameters\n\n\n\nNo reported serious or severe adverse events\n\n\n\nNo dropouts related to drug or related to adverse events\n\n\n\n\n\n\nThese results include 4 of 5 escalating dose levels. Data are not yet available for single or multiple dose cohorts at 184 mg, the highest dose being tested\n\n\n\n\n\n\nAnnounced a planned R&D Day on June 1, 2023, which will i...